EHSG KF - CUTISS
Alternative Names: denovoSkin™; EHSG-KFLatest Information Update: 13 Feb 2024
At a glance
- Originator CUTISS
- Class Skin disorder therapies; Tissue transplantation therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Burns
Most Recent Events
- 05 Dec 2023 EHSG KF receives Orphan Drug status for Burns in European Union before December 2023 (Cutiss Website, December 2023)
- 05 Dec 2023 EHSG KF receives Orphan Drug status for Burns in Switzerland before December 2023 (Cutiss Website, December 2023)
- 05 Dec 2023 EHSG KF receives Orphan Drug status for Burns in USA before December 2023 (Cutiss Website, December 2023)